Beacon Pointe Advisors’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-39,700
Closed -$90.5K – 1333
2024
Q2
$90.5K Sell
39,700
-4,000
-9% -$15.3K ﹤0.01% 1230
2024
Q1
$189K Hold
43,700
– – ﹤0.01% 1277
2023
Q4
$133K Buy
43,700
+700
+2% +$1.32K ﹤0.01% 1257
2023
Q3
$61.9K Buy
+43,000
New +$83.2K ﹤0.01% 1303
2022
Q4
– Sell
-13,200
Closed -$164K – 1113
2022
Q3
$164K Buy
13,200
+1,300
+11% +$14.9K ﹤0.01% 943
2022
Q2
$58K Buy
11,900
+400
+3% +$2.22K ﹤0.01% 1021
2022
Q1
$87K Buy
+11,500
New +$109K ﹤0.01% 1163

Beacon Pointe Advisors's GTHX Position: Q3 2024 in Review

Beacon Pointe Advisors sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 39,700 shares — an estimated $90.5K sold.

Beacon Pointe Advisors first reported a position in GTHX in Q1 2022 and held it in 7 quarters. The position peaked at $189K in Q1 2024. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Beacon Pointe Advisors reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Beacon Pointe Advisors sold 39,700 G1 Therapeutics shares in Q3 2024, an estimated $90.5K.
  • Beacon Pointe Advisors first reported a position in G1 Therapeutics in Q1 2022 and held it in 7 quarters.
  • Beacon Pointe Advisors's G1 Therapeutics position peaked at $189K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Beacon Pointe Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.